print_label | resize_label

EXPLORE THE ONGLYZA MECHANISM OF ACTION

Discover how ONGLYZA® (saxagliptin) helps reduce blood glucose by prolonging GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) incretin activity in a glucose-dependent manner.

1

THE ROLE OF INCRETINS

IN GLUCOSE HOMEOSTASIS

Eating increases levels of glucose   in the body.

In response to increased levels of glucose, the small intestine increases production and release of GLP-1 and GIP incretins  into the bloodstream. These hormones contribute to glucose homeostasis.

Response of eating and increased production of hormones GLP-1 and GIP incretins in the blood stream
Response of eating and increased production of hormones GLP-1 and GIP incretins in the blood stream
1

THE ROLE OF INCRETINS

IN GLUCOSE HOMEOSTASIS

Eating increases levels of glucose   in the body.

In response to increased levels of glucose, the small intestine increases production and release of GLP-1 and GIP incretins   into the bloodstream. These hormones contribute to glucose homeostasis.

 
2

THE ROLE OF DPP-4

IN THE LIFESPAN OF INCRETINS

The enzyme DPP-4 (dipeptidyl peptidase-4) begins degrading the GLP-1 and GIP incretins   within minutes of their release. Consequently, GLP-1 and GIP are short-lived, disrupting glucose homeostasis.

2

THE ROLE OF DPP-4

IN THE LIFESPAN OF INCRETINS

The enzyme DPP-4 (dipeptidyl peptidase-4) begins degrading the GLP-1 and GIP incretins   within minutes of their release. Consequently, GLP-1 and GIP are short-lived, disrupting glucose homeostasis.

3

HOW ONGLYZA WORKS

TO INHIBIT DPP-4

ONGLYZA is a DPP-4 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings.

ONGLYZA inhibits DPP-4 enzymes for a 24-hour period, thereby prolonging the body’s own action of naturally secreted incretins GLP-1 and GIP.

3

HOW ONGLYZA WORKS

TO INHIBIT DPP-4

ONGLYZA is a DPP-4 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings.

ONGLYZA inhibits DPP-4 enzymes for a 24-hour period, thereby prolonging the body’s own action of naturally secreted incretins GLP-1 and GIP.

4 HOW ONGLYZA MAY HELP TO LOWER A1C

GLP-1 signals to the pancreas to decrease glucose secretion by pancreatic alpha cells, which decreases hepatic glucose productions.

GLP-1 and GIP increase insulin release by signaling the pancreatic beta cells, which increase uptake of glucose by the muscle, fat, and peripheral tissues.

By inhibiting DPP-4, ONGLYZA helps to reduce fasting plasma glucose (FPG), and postprandial glucose (PPG) in a glucose-dependent manner, which helps to reduce blood glucose levels and A1C.

CONSIDER ONGLYZA

FOR YOUR APPROPRIATE ADULT PATIENTS WITH TYPE 2 DIABETES, IN ADDITION TO DIET AND EXERCISE

START treatment in renally impaired patients on 2.5 mg*

*Moderate to severe, or ESRD requiring hemodialysis. Assessment of renal function is recommended prior to initiation of ONGLYZA and periodically thereafter.

OR

ADD-ON to commonly used oral agents such as metformin

When individualizing treatment for your patients, hypoglycemia and renal function may be a concern: